Abstract
IntroductionThis study aimed to elucidate the prognostic value of microRNAs (miRNAs) in patients with osteosarcoma.Materials and MethodsStudies were recruited by searching PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang data-bases (final search update conducted January 2017). Eligible studies were identified and the quality was assessed using multiple search strategies.ResultsA total of 55 articles that investigated the correlation between miRNA expression and either patient survival or disease recurrence in osteosarcoma was initially identified. Among these, 30 studies were included in the meta-analysis. The results of our meta-analysis revealed that elevated levels of miR-21, miR-214, miR-29, miR-9 and miR-148a were associated with poor prognosis in osteosarcoma. Additionally, downregulated miR-382, miR26a, miR-126, miR-195 and miR-124 expression indicated poor prognosis in osteosarcoma.ConclusionsmiRNAs may act as independent prognostic factors in patients with osteosarcoma and are useful in stratifying risk.
Highlights
This study aimed to elucidate the prognostic value of microRNAs in patients with osteosarcoma
The results of our meta-analysis revealed that elevated levels of miR-21, miR-214, miR-29, miR-9 and miR-148a were associated with poor prognosis in osteosarcoma
Conclusions: miRNAs may act as independent prognostic factors in patients with osteosarcoma and are useful in stratifying risk
Summary
This study aimed to elucidate the prognostic value of microRNAs (miRNAs) in patients with osteosarcoma. Osteosarcoma is the most common bone malignancy with an incidence of 4–5 cases per million people [1] It usually develops in the proximal humerus, proximal tibia, and metaphyseal regions of the distal femur. With the development of multidisciplinary treatments, the five-year survival rate has significantly improved to approximately 60–70% in patients with localized tumor. It is difficult diagnose osteosarcoma during the early disease stages, and approximately half of all patients develop metastases. These patients with metastasis or recurrence have a low 5-year survival rate [2]. The biomarkers with most potential as prognostic factors are the microRNAs (miRNAs)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
